

Survey on the HCP perspectives on CINV in stem cell transplant

Outcomes report

Updated 15.11.2022



Survey on the HCP perspectives on CINV in stem cell transplant

Final results

Completers 348 116% of goal

- Activity dates: 17 May 2022 to 17 August 2022
- Target Audience: haemato-oncologists in Europe
- Provided by Ology Medical Education
- Survey language: English



Survey on the HCP perspectives on CINV in stem cell transplant

A web-based questionnaire independently developed with expert faculty with the intention of uncovering:

- Unmet needs in chemotherapy-induced nausea and vomiting (CINV) in patients undergoing stemcell transplant (SCT)
- The healthcare professional's (HCP) perspective on CINV in patients undergoing SCT
- Educational gaps in CINV in patients undergoing SCT, as identified by HCPs

Expert faculty:

Karin Jordan, MDUniversity Hospital Heidelberg, Heidelberg, Germany

Nicola Di Renzo, MD
Vito Fazzi Hospital, Lecce, Italy


Florian Strasser, MD
Cantonal Hospital St. Gallen, St. Gallen,
Switzerland

Results - Demographics


Data gathered from N=348 completers

Demographics

How many years have you been in practice as a haemato-oncologist?




How many patients undergoing stem cell transplantation (SCT) do you see, on average, per year?




Demographics continued


In which European country do you practise?




Do you see patients requiring allogeneic SCT, autologous SCT, or both?



Approximately what percentage of your patients with multiple myeloma, leukaemia, or lymphoma require allogeneic SCT?




Approximately what percentage of your patients with multiple myeloma, leukaemia, or lymphoma require autologous SCT?



Results - Unmet needs and HCP perspectives

Data gathered from N=348 completers

In your institution, approximately what percentage of your patients requiring SCT experience chemotherapy-induced nausea and vomiting (CINV) affecting their quality of life (QoL) and/or functioning despite receiving local standard antiemetic prophylaxis?



In your institution, how do you measure and monitor CINV in patients undergoing SCT?

- 53% Nursing assessment, with communication to oncologist if needed
- Symptom assessment instrument questionnaire on paper for all patients
- 11% Mobile app for all patients
- 10% "Distress Thermometer" for all patients
- Electronic patient-reported outcomes (PRO) assessment tool for all patients
- 0% Other

In patients undergoing SCT, how do you personally define CINV that impacts patients' QoL and/or functioning?

Mental impact:

- Sad/sadness/not happy (5)
- Depression (4)
- Distressful and troublesome/psychologic distress (2)
- Anxiety
- Demotivating
- Debilitating

Feeling:

- Not okay/not good/bad/not feel the same/ not normal for a time (7)
- Times of ill/ill/some of the time feel ill, others not (3)
- Sometimes high, sometimes low

QoL:

- Impact on relationships (family/friends/love) (5)
- Negatively impacted QoL (4)
- (Very) poor QoL (2)
- Change in QoL (in short time) (2)
- QoL: sometimes poor sometimes good
- Impossible to have QoL
- Diminished life
- Low-quality social life
- Missed work
- Finances

In patients undergoing SCT, how do you personally define CINV that impacts patients' QoL and/or functioning? (cont.)

Symptoms:

- Periods of/lots of/persistent/continuous nausea/vomiting (17)
- Nausea limiting eating for > 5 days
- 3-5 events/day and/or npt request
- Loss of appetite/nutrition/weight due to nausea and vomiting (9)
- Dehydration (2)
- Development of symptoms
- Stomach issues/uneasy stomach
- Renal symptoms
- Gastrointestinal disturbance
- Fatigue

Function:

- Reduced (daily) functioning/poor function (3)
- Loss of activity
- Sitting down too much
- Periods of time in which you need to consider what you do, and what you wear


Definition:

- Patient reported/questionnaire (2)
- Data-based (2)
- Scale rating
- CTCAE Grading system


Other:

- Necessary evil
- New normal
- Best option and necessary


In your institution, which of the following classes of agent are used to prevent CINV in patients receiving conditioning treatment with highly emetogenic chemotherapy for SCT?




What do you think are the three most important current challenges in managing CINV in patients undergoing SCT?



In your opinion, how confident are the healthcare professionals (HCPs) in your institution, including yourself, that they can provide optimal control of CINV in patients undergoing SCT?



In your opinion, what is the preferred method of administration of antiemetic prophylaxis for patients undergoing SCT in your institution?



Why is the below antiemetic prophylaxis the preferred option?

Oral:

- Easy/simple/convenient (15)
- Effective/efficacy (4)
- Preventative (2)
- Initially (2)
- Patient preference (2)
- Fast (1)
- Data-based
- I prefer oral only for patients who are very compliant
- Adults


Intravenous:

- Vomiting/CINV/non-swallowed (13)
- Faster/quicker (8)
- Low risk/less risk/minimal risk/low emetic risk (4)
- Easy/convenient (4)
- Bloodstream/goes in system/in-body (3)
- Used more/more info/recommended (3)
- Patient-dependent (3)
- Effective/higher efficacy (3)
- Overuse (2)
- Compliance (2)
- Monitor
- Data-based
- Reliable
- Quality
- Mental issues
- Adults
- Physical burden
- Specific indication


Results – Educational gaps

Data gathered from N=348 completers


How familiar are you, and in your opinion the HCPs in your institution, with the current guidelines for CINV for patients receiving high-dose chemotherapy for SCT?



How do you wish to be adequately and timely informed about clinical-practice-changing care updates to CINV strategies?



In your opinion, how well are the latest CINV strategies for patients undergoing SCT implemented in haemato-oncology societies' standard-of-care guidelines?



What do you think are the major gaps in medical education on CINV management for patients undergoing SCT?

- Insufficient representation of SCT specialists in supportive-care educational boards/groups
- Lack of interprofessional education (e.g. SCT oncologists together with specialized nurses)
- Insufficient institutional support to invest working time in CINV education
- Insufficient awareness of the impact CINV has on the QoL and functioning of patients undergoing SCT
- Insufficient funding for participation (for educational events with costs or travel)

Audience generation

The program has been advertised via an e-blast campaign

E-blasts



We need your opinion on CINV treatment



Survey of the HCP perspective on CINV in SCT

Your expert insight needed

We are inviting you to provide us with your professional insight by completing a web-based questionnaire, developed by expert faculty, on chemotherapy-induced nausea and vomiting (CINV) in patients undergoing stem-cell transplant (SCT). This short questionnaire features multiple choice and free-text questions; we hope that responses from haemato-oncologists in Europe, such as yourself, will provide us with information on:

- Unmet needs in CINV in patients undergoing SCT
- The healthcare professional's (HCP) perspective on CINV in patients undergoing SCT
- Educational gaps in CINV in patients undergoing SCT, as identified by HCPs

START SURVEY

Chair

Karin Jordan, MD, University Hospital Heidelberg, Heidelberg, Germany

Faculty

Nicola Di Renzo, MD, Vito Fazzi Hospital, Lecce, Italy

Florian Strasser, MD, Cantonal Hospital St. Gallen, St. Gallen, Switzerland



Provided by Ology Medical Education.

This survey is made possible by an unrestricted educational grant from Helsinn Healthcare SA.

This is an independent survey designed by expert faculty and does not meet the criteria for adverse event reporting. Please do not include details of specific adverse events, and ensure any such events are reported separately through the appropriate channels.





Inform & Inspire